A pharmacological study demonstrated that MK-2947 effectively ameliorates angiogenic performance and blunts the myofibroblast-like profibrotic phenotype of SSc dermal microvascular endothelial cells (SSc-MVECs), thus providing new evidence for the benefit of repurposing sGC stimulators for SSc (Romano et al., 2023). The gene discussed is SGCB; the disease is systemic sclerosis.